Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320

Tel: 805-447-1000

Visit website

Email Us

LIVE. WIN. THRIVE.

We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.

Join Us

Employee Testimonials

“Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”

Jorge D.
Porcess Scientific Director
Juncos, PR
“Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”

Fernando F.
Executive Director Plant Manager
Rhode Island, US
“Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”

Niria R.
Specialist Quality Control
Juncos, PR

Diversity and Inclusion
Benefits
Community Investment
Awards and Accolades

Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.

Learn More

We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.

Learn More

Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen

Learn More

Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.

Learn More

NEWS

Policy

A Deep Dive into Teva Pharma Financials Shows Significant Weakness and Optimism

Last week, Teva Pharmaceutical released what tried to be an optimistic second-quarter financial report, despite revenues that had decreased by 18 percent and softening sales of its biggest product, Copaxone.

August 9, 2018

3 min read

Mark Terry

Business

Pharma Companies Create Memorable Ad Campaigns for Branded Products

The pharma industry has developed ad campaigns to tout the efficacy of its branded products to consumers, often using celebrities to add his or her personal stamp onto a pharmaceutical product.

August 8, 2018

3 min read

Alex Keown

Pictured: Pile of money/iStock, Ihor Lukianenko

Business

Regeneron’s Founder Speaks Out on U.S. System for Pricing Drugs

It’s pretty easy to complain about the price of drugs. Drug companies typically spend billions of dollars to develop a drug, and often spend billions of dollars to develop drugs that never get approved. But a surprising critic of the U.S. system of pricing drugs is Leonard Schleifer.

July 30, 2018

3 min read

Mark Terry

Business

2 Top Amgen Executives Leaving the Company

Two of Amgen’s executive vice presidents are leaving the company.

July 27, 2018

2 min read

Mark Terry

Business

Alector Closes $133 Million to Expand Alzheimer’s Programs

South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.

July 25, 2018

3 min read

Mark Terry

Business

AbbVie Strikes Deal With Mylan to Delay Humira Biosimilar Challenge

AbbVie continues to do what it can to protect its Humira-driven revenue stream. This morning the company inked an agreement to grant Mylan the rights to begin marketing its biosimilar to Humira in the United States in 2023.

July 17, 2018

2 min read

Alex Keown

Drug Development

Amgen and UCB Take Another Shot at Osteoporosis Drug

Amgen and UCB resubmitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Evenity (romosozumab).

July 13, 2018

2 min read

Mark Terry

FDA

Investigation Examines Big Pharma Payments to FDA Advisers

Has the U.S. Food and Drug Administration failed to do its due diligence in finding and reporting financial conflicts of interest between members of its scientific advisory committees and pharmaceutical companies?

July 6, 2018

3 min read

Alex Keown

Policy

FDA Withdraws Draft Guidance on Biosimilar Development

The U.S. Food and Drug Administration withdrew its draft guidance on statistical methods to evaluate the analytical similarity between branded drugs and biosimilars.

July 2, 2018

3 min read

Alex Keown

JOBS